H.I.G. WhiteHorse Europe Finances Stordata
26.3.2024 16:30:00 EET | Business Wire | Press release
H.I.G. WhiteHorse Europe, a credit affiliate of global investment firm H.I.G. Capital ("H.I.G.") is pleased to announce that it has arranged a financing package for Stordata (the “Company”).
Founded in 1988, and headquartered in Versailles, France, Stordata has established itself as a reference partner for the digital transformation of mid-size and large companies, with around 500 clients. An expert in architecture, administration, and maintenance of security and data management systems, particularly in the cloud, the Company provides critical continuous access services to its clients. The services allow clients to leverage their data in a complex and constantly evolving IT environment. The Company has experienced sustained growth in recent years and is developing additional service offerings around cybersecurity and cloud services.
Stordata is embarking on a new chapter in its development through the acquisition of a majority stake by funds advised by Elyan Partners (“Elyan”), a member of the Edmond de Rothschild Private Equity partnership from the founders and executives of the Company, who are reinvesting in the Company.
H.I.G. WhiteHorse Europe has arranged a bespoke financing package, which will be used to finance the acquisition and provide additional capital to support the Company’s expansion, especially through an active buy-and-build strategy.
H.I.G. WhiteHorse Europe, through some of its affiliates, acted as the sole arranger, while Caisse d’Epargne et de Prévoyance Hauts de France participated in the financing alongside H.I.G. WhiteHorse.
Marc Michel, Co-Founder, and Olivier Teichman, CEO of Stordata, said: “Stordata’s success is built on the technical expertise of our employees, the quality of service delivered to our clients, and the trust placed in us by our technology partners. We are so grateful for their continued support. We are also excited by our new partnership with Elyan and appreciative of the confidence we received from H.I.G. WhiteHorse and Caisse d’Epargne et de Prévoyance Hauts de France. We believe Stordata is poised for a robust growth phase.”
Jeremie Melin and Vincent Manes, Partners at Elyan said: “We have been impressed by what Stordata has built over the past years. We are convinced that it can be the foundation of an ambitious growth in France and in Europe, to offer even more value and expertise to Stordata’s clients, particularly in cybersecurity and in the cloud. With H.I.G. WhiteHorse and Caisse d’Epargne et de Prévoyance Hauts de France, we believe we have the right like-minded partners who understand the business and share common values and vision.”
Pascal Meysson, Head of H.I.G. WhiteHorse Europe, said: “Stordata has embarked on a remarkable growth journey in recent years, leveraging its expertise in security and data management, further reinforcing its position in the French digital transformation sector. We are excited to partner with a very experienced investor in Elyan and to contribute to the future success of the Company via a tailor-made financing.”
Charles Bourgeois, Managing Director at H.I.G. WhiteHorse Europe, said: “We are delighted to support Stordata and Elyan. We have been impressed by Stordata’s very high level of expertise and by the quality of its management team. Stordata's strong market reputation and significant market share have firmly established the company as the market leader among mid- and large-size clients.”
About Stordata
Stordata is an independent expert in data and virtualization, combining consulting, transformation management, administration, and maintenance of data security and management systems. Its cloud offering (StorCloud) is ISO27001 and HDS (Hébergeurs de Données de Santé - Health Data Hosts) certified.
About H.I.G. Capital
H.I.G. Capital is a leading global alternative investment firm with $60 billion of capital under management.* Based in Miami, and with offices in Atlanta, Boston, Chicago, Dallas, Los Angeles, New York, and San Francisco in the United States, as well as international affiliate offices in Hamburg, London, Luxembourg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro, São Paulo, and Dubai, H.I.G. specializes in providing both debt and equity capital to middle market companies, utilizing a flexible and operationally focused/ value-added approach:
- H.I.G.’s equity funds invest in management buyouts, recapitalizations, and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
- H.I.G.’s debt funds invest in senior, unitranche, and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. also manages a publicly traded BDC, WhiteHorse Finance.
- H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.
- H.I.G. Infrastructure focuses on making value-add and core plus investments in the infrastructure sector.
Since its founding in 1993, H.I.G. has invested in and managed more than 400 companies worldwide. The Firm’s current portfolio includes more than 100 companies with combined sales in excess of $53 billion. For more information, please refer to the H.I.G. website at hig.com.
About Elyan Partners & ERES IV
Elyan Partners SAS is a financial investment advisor and partner of Edmond de Rothschild Private Equity. Elyan is the exclusive advisor to the ERES funds and an advisor to the Privilege funds of the Edmond de Rothschild Group. Edmond de Rothschild Equity Strategies IV SLP (“ERES IV”) invests in medium-sized companies in Europe and North America.
Edmond de Rothschild Private Equity is the trade name of the Edmond de Rothschild Group’s private equity entities and has over CHF 3.6 billion of assets under management. Founded in 1953, the Group had nearly CHF 158 billion in assets under management as of 31 December 2022, 2,500 employees, and 30 offices worldwide.
*Based on total capital raised by H.I.G. Capital and affiliates.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326501486/en/
Contact information
Pascal Meysson
Head of H.I.G. WhiteHorse Europe
pmeysson@hig.com
Charles Bourgeois
Managing Director
cbourgeois@hig.com
H.I.G. WhiteHorse Europe
P +44 (0) 207 318 5700
hig.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
